Estados Unidos - inglês - NLM (National Library of Medicine)

atomy co., ltd. - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37) - titanium dioxide 3.16 g in 40 ml - purpose: sunscreen

Estados Unidos - inglês - NLM (National Library of Medicine)

atomy co., ltd. - titanium dioxide 18.310%, zinc oxide 1.920% - titanium dioxide 2.19 g in 12 g - sunscreen agent

Estados Unidos - inglês - NLM (National Library of Medicine)

atomy co., ltd. - titanium dioxide 18.31%, zinc oxide 1.92% - titanium dioxide 2.19 g in 12 g - sunscreen agent

Estados Unidos - inglês - NLM (National Library of Medicine)

atomy co., ltd. - titanium dioxide 18.31%, zinc oxide 1.92% - titanium dioxide 2.19 g in 12 g - sunscreen agent

Estados Unidos - inglês - NLM (National Library of Medicine)

atomy co., ltd. - titanium dioxide 18.31%, zinc oxide 1.92% - titanium dioxide 2.19 g in 12 g - sunscreen agent

Estados Unidos - inglês - NLM (National Library of Medicine)

atomy co., ltd. - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - octinoxate 4.08 mg in 60 ml - purpose: sunscreen

Estados Unidos - inglês - NLM (National Library of Medicine)

atomy co., ltd. - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - octinoxate 4.08 mg in 60 ml - purpose: sunscreen

Estados Unidos - inglês - NLM (National Library of Medicine)

daiichi sankyo inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - amlodipine 5 mg - azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with azor. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, ev

Estados Unidos - inglês - NLM (National Library of Medicine)

physicians total care, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - amlodipine 5 mg - azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents  , to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with azor.  control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, eval

Estados Unidos - inglês - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with azor. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, ev